Sumitomo Pharma America
NEWS
It was another busy week for clinical trial updates and news. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
It was a busy week for clinical trial updates. Here’s a look.
Relugolix is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist.
The company presented the data at the American Society of Clinical Oncology Virtual Scientific Program and also published data simultaneously in the New England Journal of Medicine.
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.
This morning, the Switzerland-based company said its SPIRIT-2 study met its co-primary efficacy endpoints and six key secondary endpoints for endometriosis treatment.
It was a very busy week for clinical trial news. Here’s a look.
Myovant to Seek Regulatory Approval of Uterine Fibroid Treatment Following Positive Late-Stage Trial
More than five million women suffer from symptoms of uterine fibroids, with more than half of them estimated to have received inadequate treatment. However, new data released by Myovant shows that concerns of inadequate treatment could soon change.
JOBS
IN THE PRESS